Advertisement
Screener

ZYMEWORKS INC. (ZYME) Executive Pay versus Performance: Pay versus Performance

ZYMEWORKS INC. Pay versus Performance

The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.

  • 2024-12-31: Other NEO average total compensation $2.45M.
  • 2023-12-31: Other NEO average total compensation $1.67M.
  • 2022-12-31: Other NEO average total compensation $1.56M.
Fiscal year endPEOPEO total compensationPEO compensation actually paidOther NEO average total compensationOther NEO average compensation actually paidTotal shareholder returnPeer group total shareholder returnNet incomeCompany-selected measureProxy filed
2024-12-31$2.45M$3.42M$89.32-$122.70M2025-11-10
2023-12-31$1.67M$2.08M$63.39-$118.70M2025-11-10
2022-12-31$1.56M$1.22M$47.96$124.30M2025-11-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Biohaven Ltd. (BHVN)United States$1.990B-3.83
COMPASS Pathways plc (CMPS)$1.812B-4.87
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Septerna, Inc. (SEPN)United States$1.783B-63.01
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Xencor Inc (XNCR)United States$1.776B-7.33